Beyond Weight Loss: The Heart Health Benefits of GLP-1 Medications

GLP-1 receptors are located on the cells in the heart. This has recently been of great interest to cardiologists and has opened up an entirely new dimension to how we think about these medications. Studies into Wegovy have shown that stimulating the GLP-1 receptor appears to have a positive effect on heart rate and blood pressure. The effects have been so dramatic that they've genuinely surprised researchers who've spent years studying cardiovascular disease.

A landmark study involved over 17,000 participants who had established cardiovascular disease and were overweight or obese. The researchers wanted to know whether taking semaglutide would reduce the risk of major cardiovascular events like heart attacks and strokes. The results, published in 2023, were remarkable. People taking semaglutide had a 20% reduction in major adverse cardiovascular events compared to those taking placebo. This meant fewer heart attacks, fewer strokes, and fewer cardiovascular deaths.

What made these findings particularly intriguing was that the cardiovascular benefits appeared to start very early, well before participants had lost significant amounts of weight. This suggests that semaglutide isn't just helping the heart because it helps people lose weight, though weight loss certainly contributes to cardiovascular health. Rather, the medication seems to have direct protective effects on the heart and blood vessels themselves.

Researchers believe this might be because GLP-1 receptors in the heart and blood vessels, when activated, reduce inflammation, improve the function of the lining of blood vessels, and may even help stabilise the plaques that build up in arteries and cause heart attacks.

These findings were significant enough that Wegovy has now been licensed specifically for reducing cardiovascular risk in people who are overweight or obese and have established cardiovascular disease. This means doctors can prescribe it not just for weight loss, but as a treatment to protect the heart.

Another major study looked at whether semaglutide could help protect the kidneys in people with type 2 diabetes and chronic kidney disease. The study found that semaglutide reduced the risk of kidney disease progression by 24%. There's also emerging evidence that these medications might help with other conditions related to obesity and cardiovascular health, including improvements in markers of liver health and benefits for sleep apnoea.

This is important if you are thinking about starting these medications. Yes, you might be thinking about them primarily in terms of weight loss, and that's entirely valid. But you're also potentially reducing your risk of heart attack, stroke, kidney disease, and other serious health complications. Even if your weight loss is more modest than you hoped for, you may still be gaining significant health benefits that will serve you well for years to come.